RxDoctor Payments Data

Sherry Spacek-Llanas, MD

Family Medicine · Waco, TXNPI 1568801629

Payments from drug & device makers

$10,319in general payments, 2019–2025

Across 688 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$704
  • GSK$690
  • AstraZeneca$562
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$503
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$10,289100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,319 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,986
Medicare patients
200
Services billed
2,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$112,464
MounjaroTirzepatide63$79,247
TrulicityDulaglutide65$76,696
JanuviaSitagliptin Phosphate50$50,715
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$37,256
FarxigaDapagliflozin Propanediol23$28,833
JardianceEmpagliflozin20$28,465
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$27,257
MyrbetriqMirabegron43$26,948
LinzessLinaclotide23$22,635
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,943
EliquisApixaban11$12,080
BelsomraSuvorexant23$10,427
Breo ElliptaFluticasone/Vilanterol15$7,943
GemtesaVibegron15$7,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$447$155,943128 claims
Novo NordiskOzempic$1,142$112,46474 claims
MerckJanuvia, Belsomra$376$61,14273 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$562$49,39861 claims
GSKTrelegy Ellipta, Breo Ellipta$690$45,19965 claims
Boehringer IngelheimJardiance$468$28,46520 claims
Astellas Pharma US IncMyrbetriq$415$26,94843 claims
AbbVieLinzess, Synthroid$1,354$25,45156 claims
PfizerEliquis$704$12,08011 claims
Sumitomo Pharma America, Inc.Gemtesa$98$7,06415 claims
Eisai Inc.Dayvigo$75$4,35313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →